Evidence map›Paper›PMID 38579194›Full record

ArticleJCO precision oncology2024

First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report.

Camilla O Hoff, Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, Luana G de Sousa, Adel K El-Naggar, Jordi Rodon Ahnert, Renata Ferrarotto

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. AXL Inhibitors in Oncology Clinical Trials: A Review.Journal of immunotherapy and precision oncology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Camilla O HoffDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-4618-8438
Eduardo Andreazza Dal LagoDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0003-6987-7740
Juliana Mota SiqueiraDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5373-0141
Luana G de SousaDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-3516-7105
Adel K El-NaggarDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jordi Rodon AhnertDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6467-3632
Renata FerrarottoDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-3561-215X

Funding

Exploring biomarkers of clinical benefit to VEGFR inhibitor combined with PD-L1 inhibitor in recurrent/metastatic Adenoid Cystic CarcinomaR03DE031333 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FERRAROTTO, RENATA · 2022 to 2023
$324k
NIDCR NIH HHS R03 DE031333
6 · The paper itself

Abstract

First use of AXL-targeting in adenoid cystic carcinoma (ACC); with positive results, ACC now included in AXL studies.

Indexed as

Axl Receptor Tyrosine KinaseCarcinoma, Adenoid CysticHumansAXL protein, humanAxl Receptor Tyrosine Kinase

Identifiers

PMID38579194
PMCPMC11018191

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.